September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Evaluation of Vitreous Factor in Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • Namrata Nandakumar
    Ophthalmology & Visual Sciences, Massachusetts Eye and Ear Infirmary/ Schepens, Brookline, Massachusetts, United States
  • Gianna C Teague
    Ophthalmology & Visual Sciences, Massachusetts Eye and Ear Infirmary/ Schepens, Brookline, Massachusetts, United States
  • Francisco J Lopez
    Ophthalmology & Visual Sciences, Massachusetts Eye and Ear Infirmary/ Schepens, Brookline, Massachusetts, United States
  • Walter Johnson
    Ophthalmology & Visual Sciences, Massachusetts Eye and Ear Infirmary/ Schepens, Brookline, Massachusetts, United States
  • Kameran Lashkari
    Ophthalmology & Visual Sciences, Massachusetts Eye and Ear Infirmary/ Schepens, Brookline, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Namrata Nandakumar, None; Gianna Teague, None; Francisco Lopez, None; Walter Johnson, None; Kameran Lashkari, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5452. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Namrata Nandakumar, Gianna C Teague, Francisco J Lopez, Walter Johnson, Kameran Lashkari; Evaluation of Vitreous Factor in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5452.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The pathophysiology of diabetic retinopathy (DR) is not well understood especially in terms of the roles of various factors associated with its development and progression. Currently, certain pro-angiogenic factors such as VEGF-A have been associated with progression of DR to more advanced stages. The aim of this study is identify novel factors that are associated with proliferative DR (PDR) using vitreous biopsies of subjects with PDR and control, non-diabetic subjects.

Methods : Undiluted vitreous samples were collected from healthy controls (n=28) and PDR subjects (n=35) during routine vitrectomy procedures. Control subjects included those with ocular conditions not associated with vascular disease, including epiretinal membranes, macular holes, vitreomacular traction syndrome, and vitreous floaters. PDR samples were determined by primary diagnosis of each subject. All samples were analyzed by a LuminexTM multiplex assay for detection for 31 pro-angiogenic and pro-inflammatory cytokines. Transformed data sets were analyzed by MANOVA and for false discovery. Candidate factors were further evaluated with ANCOVA.

Results : Analysis of the vitreous samples indicated that there was no significant difference in age or gender between control and PDR subjects. Significant differences between PDR and controls were observed MANOVA analysis was performed for pro-angiogenic and pro-inflammatory factors. In PDR, significant shifts observed for PLGF, VEGF-A, SCD401, PAI-1, and sVEGFR-1 (p = 0.0000002, p = 0.0022, p = 0.07, p = 0.09, and p = 0.03, respectively). Other factors were upshifted to a less degree. Data showed that some soluble receptors were downshifted in PDR compared to controls.

Conclusions : Evaluation of the vitreous in subject with PDR subjects compared with controls revealed that multiple factors are associated with the dynamic changes that occur in PDR. Due to its guarded prognosis identification of novel factors as potential therapeutic targets may advance our therapeutic strategies in management of PDR beyond anti-VEGF therapy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×